5-氟-1H-苯并咪唑-2-甲腈 | 29958-83-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 5-氟-1H-苯并咪唑-2-甲腈
• 英文名称: 2-Cyano-5-fluor-benzimidazol
• 英文别名: 5-fluoro-1(3)H-benzoimidazole-2-carbonitrile；5-fluoro-1H-benzo[d]imidazole-2-carbonitrile；6-fluoro-1H-benzimidazole-2-carbonitrile
• CAS: 29958-83-6
• 化学式: C₈H₄FN₃
• 分子量: 161.138
• InChiKey: XKOAMCIWVBHYSH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  52.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  顺式-2-甲基六氢吡咯并[3,4-c]吡咯 、 5-氟-1H-苯并咪唑-2-甲腈 在 N-乙酰-L-半胱氨酸 作用下， 以 甲醇 为溶剂， 生成 1-(5-fluoro-1H-benzimidazol-2-yl)-1-[(3aR,6aS)-5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]methanimine
  参考文献：
  名称：

  Synthesis of novel histamine H4 receptor antagonists

  摘要：

  This letter describes the discovery and synthesis of a series of octahydropyrrolo[3,4-c]pyrrole based selective histamine hH4 receptor antagonists. The amidine compound 20 was found to be a potent and selective histamine H4 receptor antagonist with moderate clearance and a high volume of distribution. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.11.098
• 作为产物：
  描述：

  4-氟-1,2-苯二胺 在 ammonium hydroxide 、 溶剂黄146 作用下， 以 乙醇 、 水 为溶剂， 生成 5-氟-1H-苯并咪唑-2-甲腈
  参考文献：
  名称：

  Synthesis of novel histamine H4 receptor antagonists

  摘要：

  This letter describes the discovery and synthesis of a series of octahydropyrrolo[3,4-c]pyrrole based selective histamine hH4 receptor antagonists. The amidine compound 20 was found to be a potent and selective histamine H4 receptor antagonist with moderate clearance and a high volume of distribution. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.11.098

文献信息

• [EN] 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS<br/>[FR] DÉRIVÉS DE PIPÉRIDINE OU PIPÉRAZINE SUBSTITUÉS PAR 1,2,4-OXADIAZOLE COMME ANTAGONISTES DE SMO
  申请人：ANGELETTI P IST RICHERCHE BIO

  公开号：WO2010013037A1

  公开（公告）日：2010-02-04

  The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts, stereoisomers or tautomers thereof which are inhibitors of the Sonic Hedgehog pathway, in particular Smo antagonists. Thus the compounds of this invention are useful for the treatment of diseases associated with abnormal hedgehog pathway activation, including cancer, for example basal cell carcinoma, medulloblastoma, prostate, pancreatic, breast, colon, bone and small cell lung cancers, and cancers of the upper GI tract.

  本发明涉及式(I)的化合物及其药学上可接受的盐、立体异构体或互变异构体，这些化合物是Sonic Hedgehog途径的抑制剂，特别是Smo拮抗剂。因此，本发明的化合物对治疗与异常Hedgehog途径激活相关的疾病有用，包括癌症，例如基底细胞癌、髓母细胞瘤、前列腺、胰腺、乳腺、结肠、骨骼和小细胞肺癌，以及上消化道的癌症。
• 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS
  申请人：Dessole Gabriella

  公开号：US20110183974A1

  公开（公告）日：2011-07-28

  The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts, stereoisomers or tautomers thereof which are inhibitors of the Sonic Hedgehog pathway, in particular Smo antagonists. Thus the compounds of this invention are useful for the treatment of diseases associated with abnormal hedgehog pathway activation, including cancer, for example basal cell carcinoma, medulloblastoma, prostate, pancreatic, breast, colon, bone and small cell lung cancers, and cancers of the upper GI tract.

  本发明涉及式(I)的化合物及其药学上可接受的盐、立体异构体或互变异构体，其是Sonic Hedgehog通路的抑制剂，特别是Smo拮抗剂。因此，本发明的化合物对治疗与异常刺猬通路激活相关的疾病有用，包括癌症，例如基底细胞癌、髓母细胞瘤、前列腺、胰腺、乳腺、结肠、骨骼和小细胞肺癌，以及上消化道癌症。
• Synthesis of novel histamine H4 receptor antagonists
  作者：Charlotte A.L. Lane、Duncan Hay、Charles E. Mowbray、Michael Paradowski、Matthew D. Selby、Nigel A. Swain、David H. Williams

  DOI：10.1016/j.bmcl.2011.11.098

  日期：2012.1

  This letter describes the discovery and synthesis of a series of octahydropyrrolo[3,4-c]pyrrole based selective histamine hH4 receptor antagonists. The amidine compound 20 was found to be a potent and selective histamine H4 receptor antagonist with moderate clearance and a high volume of distribution. (C) 2011 Elsevier Ltd. All rights reserved.